Experienced in X-Linked Spondyloepiphyseal Dysplasia Tarda

Yong M. Xia

State Key Laboratory Of Bioreactor Engineering, 
Shanghai, CN 
Experienced in X-Linked Spondyloepiphyseal Dysplasia Tarda
State Key Laboratory Of Bioreactor Engineering, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Yong Xia practices in Shanghai, China. Xia is rated as an Experienced expert by MediFind in the treatment of X-Linked Spondyloepiphyseal Dysplasia Tarda. Their top areas of expertise are Liver Cancer, Gastrointestinal Perforation, Triple-Negative Breast Cancer, Hepatectomy, and Osteotomy.

Their clinical research consists of co-authoring 553 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of X-Linked Spondyloepiphyseal Dysplasia Tarda.

Locations

State Key Laboratory Of Bioreactor Engineering, Shanghai, 200237, China
Other Locations
No. 225, Changhai Road, Yangpu, 200438, China
No. 127, Youyi West Road, Xi'an, 710071, China
Luoyu Road 1037, Wuhan, 430074, China
99 West Huaihai Road, Xuzhou, 221002, China
63 Duobao Road, Guangzhou, China
1037 Luoyu Road, Wuhan, 430074, China
R En Min South Road, Chengdu, 610041, China
1200 Cailun Road, Shanghai, 201203, China
No. 182, Tongguan Road, Lianyungang, 222002, China
No. 74 Zhongshan 2nd Road, Guangzhou, 510080, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Enrollment Status: Terminated
Publish Date: December 21, 2017
Intervention Type: Drug
Study Phase: Phase 3

553 Total Publications

Molecular Signatures of Nuclear Protein Alterations in Systemic Lupus Erythematosus across Disease Stages.
Molecular Signatures of Nuclear Protein Alterations in Systemic Lupus Erythematosus across Disease Stages.
Journal: Journal of proteome research
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xia's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 85 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile